BioCryst Pharmaceuticals announced it will discontinue its internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama by the end of 2026 as part of a strategic shift toward external innovation. The company completed enrollment in the Phase 3 ALPHA-ORBIT trial for navenibart, its investigational long-acting plasma kallikrein inhibitor for hereditary angioedema, with top-line data expected in the third quarter of 2027. BioCryst also resolved a manufacturing delay for ORLADEYO oral pellets, which will be available in early August. The company lowered its 2026 non-GAAP operating expense guidance to a range of 420 million to 440 million dollars, down from 450 million to 470 million dollars, while reaffirming its revenue outlook.
BioCryst Pharmaceuticals IncCompany closing internal discovery programs and facility, lowering operating expense guidance, indicating strategic shift and reduced internal R&D investment.